Prognostic impact of adjuvant chemoradiotherapy and genes methylation on localized urothelial carcinoma patients

Abstract

In the management of muscle-invasive urothelial carcinoma, radiotherapy serves as an important adjuvant treatment to radical cystectomy. Evidence from other cancers indicates that synchronous chemoradiotherapy is associated with enhanced local control and survival outcomes when compared to radiotherapy. In our retrospective study, we enrolled 170 patients with muscle invasive urothelial carcinoma underwent adjuvant chemotherapy, radiotherapy or synchronous chemoradiotherapy. We also conducted MSP to analyse some important genes promoter methylation status such as PTPN6 , PTPN11 and SOCS1 with these patients’ clinicopathological features. We found that chemoradiotherapy significantly improved the media OS (50.2 vs. 38.9 m) and DFS (44.3 vs. 17.4 m) both in bladder and upper tract urothelial carcinomas. Adjuvant chemotherapy or radiotherapy alone also contribute to a longer survival times of OS and DFS in the overall cohort. We also found high methylation of multiple genes (≥ 2) was significantly associated with worse clinical outcomes in urothelial carcinoma patients. Our study indicated that chemoradiotherapy or gene methylation status might be an important prognostic factors for prognosis with muscle-invasive urothelial carcinoma.